China, where the outbreak of coronavirus (Covid-19) has begun, announced the decision to launch a new flu vaccine to break the effect of the outbreak in the winter months.
China National Pharmaceutical Group has announced that the latest tests of the flu vaccine they are working on have been successful and are ready to go on the market.
China's National Pharmacy Group (CNPG) said in a statement that they are concerned about the interaction of flu disease with coronavirus in the coming autumn months and are working on the flu vaccine.
A new 'flu' vaccine for use in the coming fall will be released from today, officials said.
About China's National Pharmaceutical Group;
China National Pharmaceutical Group Inc., known as Sinopharm. (CNPGC) It is a Chinese state enterprise. The company is the indirect main shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, 51-49 joint venture with Sinopharm Industrial Investment, Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly through Sinopharm) Group Hongkong Co., Ltd.). Shanghai Shyndec Pharmaceutical (SSE: 600420, through a research institute based in Shanghai) tiantan biological products in Beijing. (SSE: 600161, through China's National Biotechnology Group).
China's National Pharmacy Group is led by the State-owned Asset scan and management commission of the Council of State.